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Rae and coworkers [1] argued that there may be selection
bias in our recently published study [2] and that, in fact, our
findings are consistent with their previously reported data.
Our study (hereafter referred to as the ‘current study’) [2]
was conducted to validate whether polymorphisms in genes
that encode metabolic enzymes may predict the response to
tamoxifen among oestrogen receptor (ER)-positive postmeno-
pausal breast cancer patients randomly assigned to treat-
ment with or without tamoxifen. The initial trial was begun in
1976 in Stockholm, Sweden and patient material from
approximately one-third of the initial population was available
for use in the current study. In the Materials and method
section of the report we compared characteristics such as
lymph node status, ER status and tumour size between the
initial and current study populations, and found that these
parameters were similarly distributed throughout the
populations. However, despite these similarities, selection
bias could not be completely excluded, and this was noted in
our conclusion, as was the need for confirmation of our
findings in a larger randomized trial.
Initially, we assessed possible differences in prognostic value
between genotypes of CYP2D6 and SULT1A1 in the study
population (including both ER-negative and ER-positive
patients). However, the primary aim was to investigate
whether these genotypes could predict response to
tamoxifen therapy in ER-positive patients. Strikingly, patients
with different CYP2D6 genotypes responded differently to
therapy. We found no variation in distant recurrence-free
survival among homozygous carriers of the CYP2D6*1 allele,
but a significant difference was noted in carriers of the
CYP2D6*4 allele. Recently, Nowell and coworkers [3]
conducted a similar study in which they investigated the
same CYP2D6 polymorphism in patients either receiving or
not receiving tamoxifen treatment. They found that the
CYP2D6*4 variant allele appeared to be associated with
decreases in death and recurrence rates. To our knowledge,
no previous studies have been performed to elucidate the
predictive value of CYP2D6 genotypes on tamoxifen
treatment.
Rae and colleagues [1] interpret our data as consistent with
their findings, suggesting that CYP2D6 poor metabolizers
may derive less benefit from tamoxifen treatment. We
disagree with that view. In support of their conclusion, Dr Rae
and colleagues cite a meeting abstract of a study in which all
patients were treated with tamoxifen and were not
randomized according to tamoxifen treatment [4]. Our
analysis represents a different comparison than that reported
by Goetz and coworkers because, even though the sample
population sizes are similar, result interpretation is highly
dependent on randomization and study design. In our opinion
we cannot endorse Dr. Rae’s statement that our findings are
consistent with their data.
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